EpiBone, Inc.
StreetZero Signal 62
About EpiBone, Inc.
EpiBone, Inc. is a privately-held regenerative medicine company focused on skeletal reconstruction. Sitting at the intersection of biology and engineering, the company harnesses the power of cells to create living solutions that have the potential to integrate seamlessly into patients' bodies. EpiBone is currently developing a pipeline of bone, cartilage, and other skeletal tissue products. The company engineers living anatomically precise and functionally mature bone grafts from autologous stem cells derived from fat aspirates.
LATEST FUNDINGCrowdfunding
$1.2M
Announced 2026-10-15
TOTAL RAISED$48.6M
IN THE NEWS
- 🔗 EpiBone, Inc. Secures Funding Round Led by Kendall Capital Partners to Accelerate Global Expansion of Clinical Trials
- 🔗 Epibone - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 EpiBone, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
- 🔗 Firm | SBIR
- 🔗 EpiBone – an Unreasonable company
EMPLOYEES—
FOUNDED2013
HQNew York, NY, United States
Industry
Crowdfunding
Tags
Regenerative MedicineBiotechSkeletal ReconstructionClinical Stage
Key highlights
- FDA IND approval received in July 2023 for Phase 1/2 cartilage product trial.
- Phase 1/2 bone product clinical trial completed in August 2023.
- Total equity funding of $45.8M plus $3M in grants raised to date.
- Recent $1.235M convertible note will fund expansion of clinical trials into medical tourism hubs such as Dubai.
Ask StreetZero about EpiBone, Inc.
Put our AI to work on this deal.
Similar companies
Other Crowdfunding deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account